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Statement of Translational Relevance 
 
 
The estrogen receptor alpha (ERα) is routinely assessed in breast cancer to inform clinical 
management. More recently, the androgen receptor (AR) has been shown to be of potential 
prognostic value, but the appropriate cut-point for robust prognostication has yet to be established. 
In this study, an optimal cut-point for AR was determined using ROC analysis with a test cohort 
and its prognostic capacity validated in an independent cohort. Prognostic capacity was robust with 
a high (78% positivity) cut-point but not with lower (1% - 10%) positivity cut-points commonly 
used in previous studies. The 78% cut-point was valid for unselected cases and selected ERα 
positive cases. Among the latter, an AR:ERα positivity ratio indicative of comparable receptor 
expression or AR predominance was associated with the best survival outcome. Determination of 
the AR status in addition to ERα in breast tumors provides important prognostic information 
providing an optimal cut-point is utilized. 
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Abstract 
Purpose: Consensus is lacking regarding the androgen receptor (AR) as a prognostic marker in 
breast cancer. The objectives of this study were to comprehensively review the literature on AR 
prognostication and determine optimal criteria for AR as an independent predictor of breast cancer 
survival. 
Experimental Design: AR positivity was assessed by immunostaining in two clinically-validated 
primary breast cancer cohorts (training cohort n=219; validation cohort n=418; 77% and 79% 
estrogen receptor alpha (ERα) positive, respectively). The optimal AR cut-point was determined by 
ROC analysis in the training cohort and applied to both cohorts. 
Results:  AR was an independent prognostic marker of breast cancer outcome in 22/46 (48%) of 
previous studies that performed multivariate analyses. Most studies used cut-points of 1% or 10% 
nuclear positivity. Herein, neither 1 nor 10% cut-points were robustly prognostic. ROC analysis 
revealed a higher AR cut-point (78% positivity) provided optimal sensitivity and specificity to 
predict breast cancer survival in the training (HR 0.41, P=0.015) and validation (HR 0.50, P=0.014) 
cohorts. Ten-fold cross validation confirmed the robustness of this AR cut-point. Patients with ERα 
positive tumors and AR positivity >78% had the best survival in both cohorts (P<0.0001). Among 
the combined ERα positive cases, those with comparable or higher levels of AR (AR:ERα positivity 
ratio >0.87) had the best outcomes (P<0.0001). 
Conclusions: This study defines an optimal AR cut-point to reliably predict breast cancer survival. 
Testing this cut-point in prospective cohorts is warranted for implementation of AR as a prognostic 
factor in the clinical management of breast cancer. 
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Introduction 
 
Androgen receptor (AR) expression is highly prevalent in primary breast cancers, ranging from 53-
99% depending on the characteristics of the cohort analyzed, the assay methodology and the criteria 
for positivity (1-7). Up to 90% of estrogen receptor alpha (ERα) positive tumors and approximately 
20% of ERα negative tumors are also AR positive (1-7). Given the high frequency of AR 
expression in breast cancer and the availability of old and new generation agents to modulate its 
activity, there has been a resurgence of interest in targeting the AR signaling pathway to treat 
women with this disease. However, much controversy exists over how best to target AR in breast 
cancer as it appears to have pleiotropic roles dependent on disease subtype and stage of progression 
(reviewed in (8) and (9)). Strong clinical and preclinical evidence supports AR as being growth 
inhibitory in hormone sensitive, ER positive breast malignancies, a role that may be sustained 
from normal breast tissue as AR activity inhibits breast development in men and women (8, 10). 
Accordingly, non-aromatizable AR agonists such as fluoxymesterone have historically 
demonstrated an efficacy comparable to that of the selective ER modulator, tamoxifen, in 
advanced breast cancer (11, 12). However, use of androgenic agents was discontinued due to 
virilizing side effects in some women.  Development of new selective AR modulators (SARMs) 
with AR agonist activity in breast tissues may circumvent that problem and one, Enobosarm 
(GTx024), has shown promise in a phase II trial of women with advanced, hormone sensitive 
disease (13). This approach is supported by a recent preclinical study in which induction of AR 
agonist activity using a different SARM inhibited the growth of endocrine-sensitive as well as 
endocrine-resistant patient-derived breast cancer xenografts (14). However, some pre-clinical 
studies have suggested that AR antagonism is also a therapeutic option for women with ERα 
positive disease (15-17), leading to breast cancer trials with new generation AR antagonists such as 
enzalutamide (e.g. ClinicalTrials.gov Identifier: NCT02953860) currently used to treat prostate 
cancer. Antagonism of AR activity may have a clinical niche in the treatment of ERα negative, AR 
positive disease, particularly the triple negative breast cancer (TNBC) subtype, in which AR is 
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purported to have oncogenic activity (18-24). However, at µM concentrations AR antagonists can 
have off-target effects in breast cancer cells (25), suggesting that their therapeutic efficacy may not 
be mediated by inhibition of AR. 
Numerous studies have investigated whether AR is a biomarker for predicting survival of breast 
cancer, but like the potential utility and means of targeting AR, its prognostic value remains 
controversial. Disparate results among studies may be attributed to heterogeneity of breast cancer 
cohorts and differences in methodology, including the use of different cut-points for AR positivity. 
Although several meta-analyses commonly conclude that AR is associated with better outcomes in 
ERα positive disease (26-29), these analyses used population-level rather than individual patient-
level data. Moreover, most studies included in the meta-analyses of AR as a prognostic biomarker 
used cut-points that are typically those used for ERα and progesterone receptor (PR) as a predictive 
biomarker (30, 31). To date, no standardized cut-point for AR prognostication has been statistically 
defined, which most likely has contributed to conflicting results in the literature regarding AR as a 
prognostic biomarker in breast cancer.  
In the current study, we comprehensively reviewed the literature on AR prognostication for breast 
cancer survival to highlight methodological heterogeneity in previous studies, and utilized two 
clinically validated breast cancer cohorts from Australia (32) and Canada (33) with long-term 
follow-up to empirically define optimal criteria for AR to be a robust independent predictor of 
breast cancer specific survival. Since there has been interest in assessing the clinical relevance of 
different AR to ERα expression ratios in breast cancer (8, 15, 34, 35), we also evaluated this 
parameter. 
 
Methods 
Study selection for comprehensive review on AR and breast cancer specific outcome 
Primary publications that investigated the relationship between AR expression and breast cancer 
outcome were identified by searching PubMed with the terms ‘breast cancer’ and ‘androgen 
Research. 
on July 30, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 7, 2018; DOI: 10.1158/1078-0432.CCR-17-1199 
6 
 
receptor’ up to July 2017. Only studies that examined the relationship between AR level and patient 
outcome were included; there was no restriction based on methodology used to assess AR protein 
levels.  Exclusion criteria for the PubMed search included the following 1) non-English articles, 2) 
review articles, 3) no information provided for at least one of the following: disease free survival 
(DFS), relapse-free survival (RFS) or breast cancer specific overall survival (OS) and 4) duplicate 
publications/cohorts. Our comprehensive review identified a total of 53 articles (Table 1). Articles 
were divided into 3 cohort subtypes: (1) unselected (i.e. all cases); (2) ERα positive and (3) ERα 
negative cohorts, including TNBC. 
Patient Cohorts  
Prior approval for this study was obtained from the Human Research Ethics Committee of the 
University of Adelaide (H-051-2006). Two independent breast cancer cohorts (32, 33) were studied, 
both represented on tissue microarrays (TMA) consisting of replicate sample cores. For detailed 
pathological and clinical characteristics see Supplementary Table 1 and for details of 
immunostaining methods, statistical analyses and cut-point determination see Supplementary 
Methods.  
Training cohort: 219 patients with invasive ductal breast carcinoma diagnosed between 1992 and 
2002 from St Vincent's Hospital, Sydney, Australia (32). Prior approval for this TMA construction 
was obtained from the Human Research Ethics Committee of St Vincent’s Hospital, Sydney. 
Median follow up was 90 months. 
Validation cohort: 418 patients with invasive breast cancer diagnosed at Vancouver General 
Hospital, between 1974 and 1995 (33). TMAs were constructed at the Genetic Pathology 
Evaluation Centre, University of British Columbia, Vancouver, Canada with ethical approval from 
the Institutional Ethical Review Board. Median follow up was 143 months. 
Immunostaining and AR antisera 
Sections of paraffin-embedded breast cancer tissue (4 μm) from the two TMA cohorts were 
immunostained with two different AR antibodies, U407 (epitope: amino acids 200-220) (36) for the 
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training cohort) and AR-N20 (SC-816, epitope: amino acids 1–20; Santa Cruz; Dallas, TX) for the 
validation cohort. The specificity of both of these AR antibodies has been confirmed previously by 
western blot and peptide competition experiments (36, 37). Concordance of immunostaining with 
the two AR antibodies is shown in Supplementary Figure 1. Details of the AR 
immunohistochemistry methodology and scoring are contained in Supplementary Methods. Ki67 
(SP6, Neomarkers, USA; 1:200 dilution) was scored as a visual estimate of continuous percent 
positivity by a board certified clinical pathologist for both cohorts (38, 39).  
 
ROC Analysis 
ROC analysis was used to dichotomize AR and Ki67 positivity for all cases in the individual 
training and validation cohorts. Additional ROC analyses were performed for all cases and the ERα 
positive cases in the combined training and validation cohort. There were insufficient cases in the 
combined cohort to perform ROC analyses for HER2+ or ERα negative sub-groups. The optimal 
cut-points for predicting breast cancer death were determined using the Youden index (J), which 
was calculated using the formula J = max [sensitivity + specificity-1] (40). In addition to ROC 
analysis, recursive partitioning was applied to the training cohort to select the most appropriate AR 
cut-point (41).  For additional details of the statistical analyses see Supplementary Methods. 
Statistical power of the ROC-derived AR cut-point for each of the cohorts was determined using 
Minitab 17 (www.minitab.com, USA). 
 
Ten-fold Cross Validation 
Ten-fold cross validation was performed to provide evidence of the accuracy of the classifier model 
to correctly predict the AR classes generated by ROC analysis (42-44). To this end, we employed 
supervised learning to build a range of classifiers including Decision Stump, Decision Tree, 
Decision Tree with information gain and Naïve Bayse from cohort features such as tumor size and 
overall survival. Ten-fold cross-validation randomly divides the dataset into 10 sub-samples and 
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uses 9 sub-samples as training data and one sub-sample as test data. This process is repeated 10-
times. Cross-validation is a reliable statistic in supervised learning and class prediction as it avoids 
overlapping test sets. The above-mentioned analyses were performed using RapidMiner 6.0 
software (RapidMiner, Boston, USA). 
Results 
A comprehensive analysis of studies investigating AR as a biomarker of breast cancer survival  
A comprehensive review of the literature on AR as a prognostic factor in breast cancer was 
undertaken.  A total of 53 studies that assessed AR status and disease outcome in breast cancer 
using either radio-ligand binding assays (n=7), immunostaining (n=45), or reverse phase protein 
microarray (n=1) were identified in a PubMed search with the criteria outlined in Methods (Table 
1). Of these, 7 did not perform multivariate analyses. AR was predictive of breast cancer outcome 
in 22/46 (48%) of all previous studies that performed multivariate analyses. Nearly all previous 
studies used cut-points of 1% or 10% nuclear AR positivity. Among the 22 studies involving 
unselected breast cancer cohorts, most found that AR is prognostic for OS by univariate analysis, 
but only 10/22 (45%) identified AR as an independent prognostic marker of OS by multivariate 
analyses (Table 1). Among the 8 studies involving cohorts selected for ERα positive disease, 5/8 
(62%) identified AR as an independent predictor of outcome. Findings in cohorts selected for ER 
negative disease were most conflicting, with a significant association between AR expression and 
OS reported in only 7/18 (39%) of studies. Of note, 5 of these 7 studies (45-49) reported that AR 
expression conferred a survival advantage in tumors that lacked ER expression, but 2 (50, 51) 
reported a survival disadvantage (Table 1). Collectively, the studies published to date highlight the 
lack of consensus on whether AR is an independent prognostic factor for breast cancer survival in 
unselected or selected cohorts. Importantly, none of the published studies performed ROC analysis 
or used an alternative statistical approach to define the optimal cut-point for AR prognostication in 
breast cancer. The majority of studies employed an arbitrary cut-point, the most common being 1% 
or 10% AR positivity. While these cut-points, commonly used for ERα and PR as a predictive 
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biomarker (30, 31), may be useful to determine AR status, they are not necessarily optimal for use 
in prognostication. 
 
 
Commonly used cut-points of AR positivity do not reliably predict breast cancer survival 
The majority (>75%) of breast cancers in the training and validation cohorts analyzed in this study 
were classified as having AR positive nuclear immunostaining irrespective of whether a 1% or 10% 
criterion was used (Supplementary Table 1). ROC analysis and the generated area under the curve 
(AUC) for all cases was used to assess how well AR positivity could distinguish between patients 
that died from breast cancer and those that survived at least 10 years. AR positivity had prognostic 
capacity in both the training (AUC=0.678, 95% CI; 0.587-0.770, P<0.0001, Figure 1A) and 
validation (AUC=0.588, 95% CI; 0.525-0.651, P=0.008, Figure 2A) cohorts. Based on the ROC 
analysis, a cut-point of 1% AR positivity, used in 14/36 of previous studies (see Table 1), resulted 
in high sensitivity for predicting breast cancer OS in the training (90.0%) and validation (93.8%) 
cohorts, but a low specificity in both instances (training: 27.5%; validation: 7.8%). Similarly, the 
commonly used cut-point of 10% AR positivity (13/36 of studies in Table 1) resulted in high 
sensitivity (training: 84.7%; validation: 85.8%) but low specificity (training: 35.0%; validation: 
18.4%) for predicting OS. Kaplan-Meier and Cox regression analyses indicated that nuclear AR 
positivity arbitrarily assigned as either >1% or >10% positivity was significantly associated with 
OS in the training cohort but not in the validation cohort (Supplementary Figure 2, Table 2, Table 
3). 
   
Defining a cut-point for AR positivity that confers robust prognostication  
As neither a 1% nor a 10% cut-point for AR positivity was prognostic for breast cancer OS in both 
the training and validation cohorts, the Youden index method, which gives equal weight to 
sensitivity and specificity, was applied to the ROC analysis to identify an optimal AR cut-point for 
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all cases in the training cohort. The highest Youden index was obtained using 77.5% AR positivity, 
which resulted in a sensitivity of 57.1% and a specificity of 75.0% for predicting breast cancer 
death. This cut-point resulted in a positive predictive value of 90.7%. An alternative method, 
recursive partitioning, identified 77% as the optimal cut-point for the training cohort to predict OS. 
The ROC determined cut-point of 77.5% (rounded to 78%) was significantly associated with ERα 
status and breast cancer subtype in both cohorts (Supplementary Tables 2 and 3, Chi Squared test). 
The frequency distributions for AR percent positivity and representative images of tumors classified 
as either high (>78% positivity) or low (<78%) AR positivity are shown for both the training and 
validation cohorts in Figure 1B-C and Figure 2B-C, respectively. Most tumors (69.4%) with AR 
positivity <78% were also ERα negative (i.e. <1% ERα positivity) in the training cohort; 73.6% 
were ERα negative in the validation cohort. A high proportion of TNBC had low AR positivity in 
both the training (79%) and validation (69%) cohorts (Supplementary Tables 2 and 3). Ten-fold 
cross validation was performed using all cases to provide evidence of the accuracy of the classifier 
model to correctly predict the two AR classes (i.e. <78% and >78% positivity) generated by ROC 
analysis. A high accuracy of 10-fold cross validation (>80%) for most of the classifiers 
demonstrated the robustness of AR positivity equal to 78% as an optimal cut-point based on cohort 
features in both the individual and combined training and validation cohorts (Supplementary Table 
4). For example, for the combined training and validation cohorts, the accuracy of Decision Tree 
with information gain criterion in prediction of AR classes <78% and >78% was 87.27% and 
90.98%, respectively (Supplementary Table 4).  
Histological grade III and progesterone receptor (PR) negative tumors were significantly associated 
with low AR positivity in the training cohort (Supplementary Table 2). The lack of an association 
between AR and PR in the validation cohort (Supplementary Table 3) is possibly the result of 
approximately one third of the cases having unknown PR values (150/418; 35.9%), whereas PR was 
measured in almost all the cases (214/219; 97.7%) in the training cohort (Supplementary Table 1).  
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Kaplan-Meier survival analyses for all cases demonstrated that an AR positivity ≥78% was 
significantly associated with OS in both the training (Figure 1D, P<0.0001) and the validation 
(Figure 2D, P=0.001) cohorts. Patients with tumor AR positivity ≥78% had approximately a 3-fold 
reduced risk of cancer-related death in the training cohort (HR=0.32, Cox regression analysis, 
P=0.001, Table 2) and a 2-fold reduced risk in the validation cohort (HR=0.51, Cox regression 
analysis, P=0.001, Table 3). AR immunostaining with a cut-point of 78% was an independent 
predictor of OS after adjusting for all other variables significant by univariate analysis in both 
cohorts (Tables 2 and 3) but was not an independent predictor of RFS (Table 2). Neither the 1% nor 
10% AR cut-points were significant by univariate analysis in the validation cohort (Table 3).  
 
AR prognosis with adjuvant therapy 
Treatment information was available for the training cohort but unavailable for the validation 
cohort. In the training cohort, AR with a 78% cut-point predicted OS (P=0.002, log rank 
statistic=9.63) in patients who received adjuvant chemotherapy (n=82; Supplementary Figure 3A), 
but not in those who did not receive adjuvant chemotherapy (n=128; P=0.067; Supplementary 
Figure 3B). AR was a significant predictor of OS in all patients irrespective of whether they did 
(n=110, P=0.014, log rank statistic=6.10, Supplementary Figure 3C) or did not (n=100, P=0.010, 
log rank statistic=6.69, Supplementary Figure 3D) receive adjuvant endocrine therapy. Similarly, 
AR predicted outcome in the ERα positive subgroup irrespective of whether patients received 
adjuvant endocrine therapy (n=89, P=0.01, log rank statistic=6.59) or not (n=67, P=0.017, log rank 
statistic=5.74).  
 
ERα positive breast cancers with high AR have the best survival outcome  
In both the training and validation cohorts, patients with ERα positive tumors (ERα >1%) that 
contained high levels of AR (i.e. ERα+, AR >78%) had significantly increased OS in comparison to 
those in the other 3 possible ERα and AR classification groups (i.e. ERα positive and AR <78%, 
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ERα negative and AR >78%, ERα negative and AR <78%; Figure 1E and 2E). Patients with ERα 
negative disease (ERα <1%) had an increased risk of death regardless of AR status, compared to 
those with ERα positive AR >78% tumors (training cohort: 11.5 and 10.3-fold risk, P<0.0001, 
Figure 1F; validation cohort: 1.9 and 2.9-fold risk, P=0.006 and P<0.0001, Figure 2F). The training 
and validation cohorts were combined for greater statistical power to assess the ability of AR to 
predict OS as a continuous variable or with an AR cut-point of <78% or ≥78% positivity. AR levels 
predicted OS in ERα positive tumors but not ERα negative tumors (Supplementary Table 5). When 
assessed by subtype, AR was an independent predictor of OS in Luminal A but not Luminal B 
cancers (Supplementary Table 5). When ROC analysis was applied to all cases or just the ERα 
positive cases in the combined training and validation cohorts, the optimal AR cut-point was 
77.95%. 
 
The AR to ERα ratio is a determinant of OS in ERα positive disease 
To investigate whether the relative levels of AR and ERα influenced OS, the training and validation 
cohorts were combined for greater statistical power and unbiased tertiles were calculated for the AR 
to ERα positivity ratio (<0.87, 0.87-1.05 and >1.05). Kaplan-Meier and Cox regression analyses 
demonstrated that patients with tumors containing comparable levels of AR and ERα (i.e. an AR to 
ERα positivity ratio approximating 1; range 0.87-1.05), or a predominance of AR (i.e. an AR to 
ERα positivity ratio >1.05) had the highest 10-year breast cancer survival outcomes (83.3% and 
80.5%, respectively; P<0.0001; Figure 3). In contrast, patients with a predominance of ERα (i.e. an 
AR to ERα positivity ratio <0.87) had a poorer survival outcome compared to patients with similar 
AR and ERα immunostaining levels (10-year breast cancer survival 71.6%; Figure 3; P<0.0001). 
Patients with tumors that were either AR or ERα negative or lacked both receptors had a lower 10-
year breast cancer specific survival rate of 53-66% (Figure 3; 3-fold increased risk of death, 
P<0.004).  ROC analysis showed that the optimal cut-point for the AR to ERα positivity ratio was 
0.82. However, in multivariate analyses, neither the AR to ERα ratio tertile groups nor an AR to 
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ERα ratio cut-point of 0.82 were independent predictors of OS in the combined training and 
validation cohorts (Supplementary Table 6A and 6B). Consistent with this, the AR to ERα ratio did 
not differentiate between luminal A and luminal B ERα positive breast cancer subgroups 
(Supplementary Table 7). 
 
Discussion 
The current study demonstrates that clinical assessment of AR in addition to ERα may permit a 
more precise prediction of breast cancer outcome in women, particularly those with hormone 
sensitive disease, providing an optimal cut-point for AR is utilized. As highlighted by our 
comprehensive review of the literature, many published studies have investigated AR as a 
prognostic factor in breast cancer, but the findings have been inconsistent resulting in doubt about 
its clinical utility for prognostication. A critical common limitation of previous studies has been the 
failure to define an optimal AR cut-point for prognosis. Rather, arbitrary cut-points of 1% and 10% 
positivity, used to determine AR status, were typically applied to dichotomize data for prognostic 
testing. Herein, we provide the first robust, statistically derived cut-point for future testing of AR as 
a prognostic factor in prospective cohorts. 
 
ROC analysis using two independent, well characterized breast cancer cohorts with 10-year follow-
up demonstrated that a cut-point of 78% AR positivity, which approximated the median value, 
achieved the best combination of specificity and sensitivity for prediction of breast cancer survival. 
This cut-point value was reinforced using recursive partitioning of the data. Ten-fold cross 
validation, a statistic used in supervised learning and class prediction, confirmed the robustness of 
the AR cut-point defined by ROC analysis. Our finding that the optimal AR cut-point approximated 
the median percentage positivity determined by immunostaining is consistent with 2 of 3 previous 
biochemical (radio-ligand binding) studies of unselected breast cancer cohorts that arbitrarily used 
the median AR protein level to dichotomize the breast cancer survival data (52-54). More recently, 
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Tokunaga et al (7) employed an arbitrary cut-point of 75% AR positivity, which approximated the 
median immunostaining, to demonstrate that AR is an independent predictor of outcome in an 
unselected breast cancer cohort. Hence, our statistically determined AR cut-point is not without 
precedence in the literature concerning AR and breast cancer prognostication when all cases are 
considered.  
AR was prognostic in this study for all breast cancer cases in both cohorts, which likely reflects its 
negative correlation with tumor size and proliferative capacity, regardless of ERα status as shown in 
this study and previously reported (3, 5, 55). A recent meta-analysis in which AR mRNA 
expression was correlated with various gene signatures in large combined breast cancer cohorts 
strongly supports this concept (26). Functionally, AR and ERα are hormone-activated nuclear 
transcription factors that regulate gene expression and are commonly co-expressed in normal and 
malignant breast epithelial cells (37, 56), indicating the potential for direct cross-talk between these 
two sex hormone receptor signaling pathways. Indeed, antagonism between AR and ERα signaling 
is thought to underpin sex-specific breast development (9). In breast cancer, this interaction and its 
functional consequence is likely to be perturbed by altered receptor levels and a pathological 
hormone milieu (8, 9, 34). 
Our data showing that a high AR cut-point is required to robustly predict survival from ERα 
positive disease is consistent with the concept that a minimum threshold of AR activity is required 
to restrain growth of ERα positive breast cancers (34, 37). Indeed, this may explain why AR 
positivity tends to be higher than ERα positivity in normal and most ERα positive malignant breast 
tissues, even though the expression of both receptors is increased in the malignant compared to the 
normal state (8). We have previously shown that exogenous AR dose-dependently inhibited ERα 
transcriptional activity from an AR to ERα molar ratio of 1:1 to 4:1 (37). This finding is in 
accordance with another study showing that an AR to ERα ratio approximating 1 was associated 
with a survival advantage in a tamoxifen-treated cohort of ERα positive patients (15). However, the 
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same study disagreed with our finding that a predominance of AR over ERα conferred a survival 
advantage, reporting that an AR to ERα ratio > 2 was associated with treatment failure on 
tamoxifen (15). In that study, AR positive tumors were defined as AR >0% positivity, which has 
only been used in 1 other immunohistochemical study (see Table 1), and AR alone did not 
independently predict outcome. Moreover, the AR=0% cases, which are well established as being 
associated with a poor prognosis, were included in the AR to ERα ratio <2 group. In our study, in 
the analysis showing that patients with tumors characterized by a predominance of ERα over AR 
had a reduced chance of survival, only tumors that were positive for both AR and ERα were 
included in the analysis. In this scenario, AR may have lost its capacity to antagonize ERα 
signaling, either due to insufficient expression or activation.  Additionally, a recent preclinical study 
showed that estrogen potentially can activate AR in a non-classical manner to facilitate ERα 
genomic activity in breast cancer cells (17). Hence, studies examining the prognostic value of AR in 
ERα positive breast cancers that included tumors with very low levels of AR expression (e.g. cut-
points of >0%, >1% or >10%) may have produced disparate results because low AR expression or 
insufficient activation cannot effectively oppose ERα activity or conditions are such that AR is 
hijacked into facilitating ERα activity. This presents a therapeutic conundrum as the latter scenario 
indicates an AR antagonist strategy whereas the former suggests an AR agonist strategy. While both 
options are supported by recent studies that have employed patient-derived xenograft models (14, 
17), the outcome of current clinical trials will provide definitive evidence regarding this 
controversy. 
AR status did not improve the stratification of ERα negative breast cancers in terms of patient 
outcome, likely due to insufficient power. In a larger study, Hu et al (3) showed that 
postmenopausal women with ERα negative breast cancers had poor survival irrespective of AR 
status. Since ERα negative breast cancers are less common than ERα positive cancers and represent 
a very heterogeneous mix of molecular disease entities, it has been difficult to definitively identify 
robust prognostic factors. However, meta-analyses of studies examining AR as a prognostic factor 
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in breast cancer have found that AR is associated with a better outcome in ERα negative disease in 
general or of its various sub-groupings (27-29). Despite the reported association of AR with a better 
outcome in this disease context, there has been much enthusiasm for therapeutic targeting of AR, 
particularly in TNBC, as there are currently no targeted therapies for the treatment of this 
aggressive disease subtype. The mainstream clinical approach has been AR antagonism based on in 
vitro and in vivo pre-clinical studies suggesting that AR has oncogenic activity in some ERα 
negative breast cancer models (18-24, 57), and two clinical trials of women with advanced TNBC 
have reported efficacy with this approach (58, 59). However, in vitro studies have demonstrated 
dichotomous proliferative effects of androgens in different AR positive ERα negative breast cancer 
cell lines (8). For example, while the MDA-MB-453 breast cancer cell line is stimulated by 
androgen in vitro (15, 20-22), other AR positive ERα negative breast cancer cell lines (MFM-223 
and CAL-148) are inhibited (25, 60). Androgenic stimulation of tumor growth has also been 
demonstrated in vivo using MDA-MB-453 xenografts (15, 22), but this has not been convincingly 
demonstrated with other ERα negative models. Rather, these studies have inferred a growth 
stimulatory effect of AR signaling in vivo by showing growth inhibition using an AR antagonist 
(bicalutamide or enzalutamide) alone (18, 23, 24). The interpretation of these studies is confounded 
by the potential for off-target effects of AR antagonists at µM doses in ERα negative breast cancer 
cells (25).  
Although the two cohorts in this study have the advantage of long-term clinical follow-up, 
treatment practices have evolved since the cohorts were assembled. Nevertheless, adjuvant 
endocrine therapy with tamoxifen or new generation ERα-target therapies remains a critical 
component of standard-of-care for women with ERα positive disease. A sub-analysis of the training 
cohort, where treatment information was available, demonstrated that AR, using a 78% cut-point, 
predicted OS in patients who received tamoxifen as adjuvant endocrine therapy. Considering our 
findings that AR is a robust independent prognostic factor for breast cancer survival in both 
unselected and selected ERα positive cases providing an appropriate cut-point was utilized, we 
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propose that studies to determine the optimal AR cut-point for selection of patients who are likely to 
respond to hormonal interventions targeting either the AR or ERα are warranted. This is particularly 
important given the recent interest in targeting AR in breast cancer, with clinical trials initiated to 
investigate either the stimulation or inhibition of this signaling pathway (ClinicalTrials.gov 
identifiers NCT00468715, NCT01597193, NCT00755885, NCT01889238, NCT01616758, 
NCT02463032 and NCT02007512). At present, there is no consensus regarding how best to select 
breast cancer patients who most likely will benefit from an AR targeted therapeutic intervention, 
highlighting the need for well-designed and validated prospective studies of AR as a predictive 
marker as well as a prognostic marker.  
 
In summary, by eliminating the use of arbitrary criteria for AR positivity to predict breast cancer 
survival, assessment of AR status could become an important clinical tool in the management of 
this disease. Since pre-clinical studies suggest a role for AR in resistance to tamoxifen (15, 61) and 
aromatase inhibitors  (62, 63), it will be important to test the prognostic power of the AR in the 
context of the cut-points defined herein using tissues collected from large contemporary, 
prospective breast cancer cohorts. 
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Tables 
 
Table 1. Summary of studies investigating Androgen Receptor as a prognostic factor in breast cancer. 
Cohorts not selected on ERα status 
Ref Year N Sample Ab Cut-point Univariate Multivariate HR (95%CI) 
(64) 1979 292 RLB - >10 fmol/mg NS ND  
(65) 1984 1181 RLB - >5 fmol/mg OS (P<0.001) ND  
(66) 1986 796 RLB - >5 fmol/mg OS (P<0.05) ND  
(67) 1990 61 RLB - >10 fmol/mg OS at 36 months 
(P=0.043) 
ND  
(54) 1992 224 RLB - >50.5 
fmol/mg 
(median)  
Yes MFS (P=0.001) NA 
(52) 1996 269 RLB - >43 fmol/mg 
(median) 
NS ND  
(68) 1996 153 Frozen - 
WS 
ARF39.3 >10% DFS (P=0.043) NS  
(69) 2006 232a TMA AR441 >10% DFS (P=0.028) NS  
(70) 2007 115 FFPE – WS AR441 >10% OS (P=0.03) NS  
(71) 2007 1087 TMA AR441 
 
Allred  
score  >3 
 NS NS  
(72) 2008 488 FFPE – WS AR441 NS RFS (P=0.023) NS  
(73) 2008 111 TMA AR441 >0 OS (P = 0.01) OS (P = 0.03) 0.46 (0.23–0.93) 
(74) 2008 138 FFPE – WS AR441 >15%  OS (P=0.01) NS  
(74) 2008 138 RLB - >30 fmol/mg RFS (P=0.007)  
OS (P=0.007) 
RFS (P<0.0001)  
OS (P=0.003) 
0.36 (0.22-0.59) 
0.4 (0.21-0.71) 
(53) 2009 347 
 
RPA NR >-0.085 
(median) 
RFS (P=0.002)  
OS (P=0.004) 
RFS (P=0.002)  
OS (P=0.013)  
0.53 (0.36-0.80) 
0.57 (0.36-0.89) 
(75) 2011 673 
 
TMA ARF39.4.1 Remmele 
score >3 
RFS (P=0.033)  
OS (P=0.023) 
 NS  
(76) 2011 335 FFPE – 
WS 
AR441 Allred score 
NR 
OS (P<0.001) OS (P<0.001) 0.31 (0.19-0.50) 
(3) 2011 1467 
 
TMA 
 
AR441 >1% 
 
Yes NS  
(77) 2012 73b TMA AR441 >1% OS (P=0.004) ND  
(2) 2012 403 
 
FFPE – WS AR27 >10% DFS (P = 0.017)  
OS (P = 0.034) 
NS  
(7) 2013 250 NR AR441 >75% DFS (P=0.0005) DFS (P=0.005) 0.46 (0.26-0.79) 
(28) 2013 109 TMA AR441 >1% DFS (P=0.026) 
OS (P=0.022) 
DFS (P=0.031) 
OS (P=0.031) 
0.24 (0.07-0.88) 
0.19 (0.04-0.86) 
(78) 2013 379 NR AR-318 Histoscore 
>10 
RFS (P<0.0001) 
OS (P<0.0001) 
RFS (P<0.0001) 
OS (P=0.0059) 
0.24 (0.12-0.50) 
0.28 (0.10-0.70) 
(79) 2014 1039 TMA AR441 >1% OS (P=0.002) ND  
(80) 2014 807 TMA AR441 >1% OS (P=0.001) ND  
(81) 2014 82 FFPE – WS AR441 Histoscore >3 OS (P=0.042) ND  
(82) 2015 1100 TMA ARF39.4.1 Histoscore Yes OS (P=0.009) 0.65 (0.47-0.90) 
(35) 2015 1026 TMA AR441 >10% DFS (P=0.025) NS  
(55) 2016 1141 TMA AR-N20 H-score >190 OS (P<0.001) OS (P=0.033) 0.80 (0.64-0.98) 
ERα Negative Breast Cancers 
(83) 2003 69c ER- FFPE – WS ARF39.4.1 >5% DFS (P=0.049) NS  
(84) 2010 226d ER-
PR- 
FFPE – WS AR27 >10% NS NS  
(85) 2007 282e TNBC 
 
TMA ARF39.4.1 Modified  
H-score >1% 
OS (P=0.04) NS  
(47) 2010 137
e
 TNBC 
 
FFPE – WS NR Score >2 OS at 5 years 
(P=0.018) 
OS at 5 years 
(P=0.047) 
NR 
(48) 2011 127
f
 TNBC TMA AR441 >10% OS (P=0.038) OS (P=0.048) NR 
(46) 2012 287
f
 TNBC TMA AR441 >5% DFS (P=0.008) DFS (P=0.032) 0.47 (0.23-0.94) 
(86) 2012 83g TNBC FFPE – WS AR441 >1% NS NS  
(87) 2013 203f TNBC FFPE – WS AR441 H-score >10% NS ND  
(88) 2014 699g TNBC TMA AR27 >1% DFS (P=0.05) ND  
(89) 2014 173f TNBC TMA ARF39.4.1 >5% OS (P=0.032) NS  
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(90) 2014 119f TNBC TMA AR441 >10% NS ND  
(91) 2014 81d TNBC FFPE – WS ARF39.4.1 >10% NS ND  
(50) 2014 492g TNBC TMA ER179 (2) >1% OS (P=0.026) OS (P=0.008) 2.16 (1.22-3.81) 
(92) 2014 52f TNBC FFPE – WS AR SP107 >10% DFS (P=0.11) 
OS (P=0.13) 
ND  
(49) 2015 45e TNBC FFPE – WS AR441 >10% OS (P=0.03) OS (0.01) 0.15 (0.04-0.59) 
(93) 2016 120g ER- FFPE – WS ZM-0437 >10% DFS (P=0.21) ND  
(51) 2016 137f TNBC TMA AR441 >45% DFS (P=0.017) DFS (P=0.012) 2.42 (1.21-4.85) 
(45) 2016 190g TNBC FFPE – WS AR441 >1% DFS (P=0.025) DFS (P=0.039) 0.36 (0.14-0.95) 
ERα Positive Breast Cancers 
(37) 2009 157
d
 TMA AR-407 >75% RFS (P=0.011) 
OS (P=0.003) 
RFS (P=0.003) 
OS (P=0.002) 
0.33 (0.20-0.85) 
0.22 (0.08-0.58)  
(94) 2010 859
g
 TMA AR441 >1% RFS (P=0.001) 
OS (P<0.001) 
RFS (P <0.0001)  
OS (P<0.0001) 
0.46 (0.30-0.71) 
0.26 (0.14-0.48) 
(6) 2011 672
d
 TMA AR441 >10% DFS (P=0.005) 
OS (P=0.032) 
DFS (P=0.049) 
NS 
0.65 (0.43-1.00) 
(95) 2013 543g TMA AR441 >1% OS (P<0.001) OS (P=0.003) 0.26 (0.11-0.62) 
(96) 2014 798g TMA AR441 >1% DFS (P=0.025) NS  
(15) 2014 192h FFPE – WS AR441 >0% NS ND  
(97) 2015 96d FFPE – WS AR441 >10% NS ND  
(93) 2016 120g FFPE – WS ZM-0437 >10% DFS (P=0.011) DFS (P=0.01) 0.25 (0.09-0.72) 
 
Abbreviations:  Ab, antibody; AR, androgen receptor; AR+, AR positive; AR-, AR negative; DFS, breast 
cancer specific relapse or breast cancer death; ER, estrogen receptor; FFPE, formalin fixed paraffin 
embedded; HR, hazard ratio; IHC, immunohistochemistry; MFS, metastasis free survival; NA, not available; 
ND, not determined; NR, not reported; NS, not significant; OS, overall survival or breast-cancer specific 
survival; PR, progesterone receptor; Ref, reference; RFS, relapse free survival; RLB, radio ligand binding 
assay; RPA, reverse phase protein microarray; TMA, tissue microarray; WS, whole section; 
a
tumor samples 
from patients who developed metastatic disease; 
b
grade III cancers; 
c
ER cut-point >5%;
 d
ER cut-point >10%; 
e
ER cut-point >0%; 
f
ER cut-point not reported; 
g
ER cut-point >1%; 
h
ER cut-point >10 pmol/mg protein; 
TNBC, triple negative breast cancer (ER-PR-HER2-); studies in bold were significant by multivariate 
analysis.  
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Table 2. Univariate and multivariate analyses for relapse-free survival (RFS) and overall survival 
(OS) (training cohort) 
 
Univariate Cox Regression  
Variable 
RFS OS 
HR 95% CI P value HR 95% CI P value 
Agea (n=219) 1.01 0.98-1.04 0.460 1.01 1.00-1.02 0.159 
Tumor sizeb (n=205) 2.18 1.27-3.74 0.005 2.34 1.24-4.40 0.009 
Gradeb (n=198) 4.90 1.19-20.17 0.028 3.68 0.89-15.29 0.072 
Lymph statusd (n=208) 3.29 1.82-5.94 <0.0001 2.42 1.25-4.68 0.008 
ERα statuse (n=204) 0.37 0.21-0.66 <0.0001 0.23 0.12-0.43 <0.0001 
PR statusf (n=205) 0.36 0.21-0.61 <0.0001 0.22 0.12-0.42 <0.0001 
HER-2/neu statusg (n=201) 2.75 1.56-4.84 <0.0001 3.06 1.60-5.87 0.001 
Ki67 statush (n=190) 2.73 1.57-4.73 <0.0001 3.42 1.77-6.61 <0.0001 
AR statusi (n=210) 0.992 0.98-1.00 0.015 0.99 0.98-1.00 0.001 
AR status 1j (210) 0.48 0.25-0.92 0.026 0.36 0.18-0.73 0.004 
AR status 10k (n=210) 0.585 0.32-1.06 0.077 0.39 0.20-0.73 0.004 
AR status 78l (n=210) 0.54 0.32-0.92 0.024 0.32 0.16-0.62 0.001 
Multivariate Analysis – AR 1% 
Variable 
RFS (n=196) OS (n=174) 
HR 95% CI P value HR 95% CI P value 
Tumor sizeb 1.58 0.85-2.82 0.150 1.43 0.70-2.92 0.313 
Tumor gradec 1.35 0.31-5.91 0.688 - - - 
Lymph node statusd 2.57 1.35-4.91 0.004 1.98 1.00-3.91 0.051 
ERα statuse 0.83 0.29-2.37 0.724 0.47 0.16-1.44 0.187 
PR statusf 0.61 0.22-1.73 0.355 0.57 0.18-1.82 0.527 
HER-2/neu statusg 1.77 0.89-3.51 0.108 1.83 0.84-3.96 0.127 
Ki67 statush 1.89 0.92-3.86 0.082 1.73 0.78-3.83 0.178 
AR status 1l 0.62 0.36-1.20 0.129 1.002 0.40-2.49 0.997 
Multivariate Analysis – AR 10% 
Variable 
RFS (n=196) OS (n=174) 
HR 95% CI P value HR 95% CI P value 
Tumor sizeb 1.57 0.85-2.92 0.152 1.43 0.72-2.88 0.309 
Tumor gradec 1.36 0.31-5.93 0.684 - - - 
Lymph node statusd 2.60 1.37-4.94 0.004 1.97 0.99-3.91 0.053 
ERα statuse 0.78 0.28-2.17 0.638 0.48 0.16-1.46 0.196 
PR statusf 0.60 0.21-1.69 0.332 0.58 0.18-1.86 0.358 
HER-2/neu statusg 1.74 0.86-3.50 0.122 1.85 0.86-3.95 0.114 
Ki67 statush 1.88 0.92-3.83 0.085 1.73 0.78-3.83 0.177 
AR status 10l 0.62 0.36-1.20 0.129 0.95 0.40-12.22 0.898 
Multivariate Analysis –AR 78% 
Variable 
RFS (n=196) OS (n=174) 
HR 95% CI P value HR 95% CI P value 
Tumor sizeb 1.53 0.80-2.76 0.181 1.38 0.74-2.57 0.369 
Tumor gradec 1.25 0.29-5.51 0.788 - - - 
Lymph node statusd 2.68 1.41-5.08 0.003 1.89 0.95-3.73 0.068 
ERα statuse 0.88 0.33-2.50 0.797 0.52 0.18-1.52 0.228 
PR statusf 0.64 0.22-1.73 0.402 0.69 0.22-2.17 0.527 
HER-2/neu statusg 1.80 0.90-3.56 0.085 2.11 1.01-4.38 0.046 
Ki67 statush 1.95 0.96-3.90 0.067 1.77 0.81-3.87 0.151 
AR status 78l 0.62 0.36-1.20 0.129 0.41 0.20-0.84 0.015 
a= Age at diagnosis (continuous variable); b = tumor size (mm) as a dichotomous variable cut-point <=20 vs >20; c = tumor grade (well or moderate vs poor); 
d = lymph node status (negative vs positive); e = ERα status (% positive cells) as a dichotomous variable cut-point <1 vs 1% positive cells; f = PR status (% 
positive cells) as a dichotomous variable cut-point <1 vs 1% positive cells; g = HER-2/neu status (negative vs positive); h = Ki67 status (% positive cells) as a 
dichotomous variable cut-point <7.5 vs 7.5% positive cells; i= AR status (% positive cells) as a continuous variable; j = AR status (% positive cells) as a 
dichotomous variable cut-point <1 vs 1% positive cells; j = AR status (% positive cells) as a dichotomous variable cut-point <10 vs 10% positive cells; l = AR 
status (% positive cells) as a dichotomous variable cut-point <78 vs 78% positive cells 
 
Research. 
on July 30, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 7, 2018; DOI: 10.1158/1078-0432.CCR-17-1199 
22 
 
Table 3. Univariate and multivariate analyses for OS (validation cohort) 
 
Univariate Cox Regression  
Variable HR 95% CI P value 
Agea 1.01 1.00-1.02 0.168 
Tumor sizeb (n=417) 1.97 1.37-2.83 <0.0001 
Gradec (n=402) 0.89 0.60-1.34 0.585 
Lymph statusd (n=370) 2.46 1.95-3.92 <0.0001 
ERα statuse (n=364) 0.53 0.36-0.77 <0.0001 
PR statusf (n=267) 0.63 0.42-0.93 0.024 
HER-2/neu statusg (n=343) 2.05 1.25-3.35 0.004 
Ki67 statush (n=367) 1.64 1.15-2.35 0.007 
AR statusi (n=376) 
AR status 1j (376) 
AR status 10k (n=376) 
0.99 
0.60 
0.79 
0.99-1.00 
0.33-1.10 
0.50-1.23 
0.008 
0.598 
0.298 
AR status 78l (n=376) 0.51 0.34-0.75 0.001 
Multivariate Analysis (n=222) 
Variable HR 95% CI P value 
Tumor sizeb 1.90 1.07-3.36 0.028 
Lymph node statusd 2.34 1.38-3.98 0.002 
ERα statuse 1.35 0.63-2.89 0.438 
PR statusf 0.59 0.30-1.14 0.116 
HER-2/neu statusg 2.72 1.34-5.48 0.005 
Ki67 statush 1.66 0.95-2.91 0.075 
AR status 78l 0.50 0.29-0.87 0.014 
a= Age at diagnosis (continuous variable) 
a = tumor size (mm) as a dichotomous variable cut-point <=20 vs >20 
b = tumor grade (well or moderate vs poor) 
c = lymph node status (negative vs positive) 
d = ERα status (% positive cells) as a dichotomous variable cut-point <1 vs 1% positive cells 
e = PR status (% positive cells) as a dichotomous variable cut-point <1 vs 1% positive cells 
f = HER-2/neu status (negative vs positive) 
g = Ki67 status (% positive cells) as a dichotomous variable cut-point <16 vs 16% positive cells 
h = AR status (% positive cells) as a continuous variable 
i = AR status (% positive cells) as a dichotomous variable cut-point <1 vs 1% positive cells 
j = AR status (% positive cells) as a dichotomous variable cut-point <10 vs 10% positive cells 
k = AR status (% positive cells) as a dichotomous variable cut-point <78 vs 78% positive cells 
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Figure Legends 
Figure 1. High AR expression is associated with an increased overall survival (OS) in the training 
cohort. (A) Receiver operating characteristic (ROC) analysis in the training cohort identified an area under 
the curve of 0.678 (95% CI; 0.587-0.770, P<0.0001). (B) Frequency distribution for AR as assessed by 
visual scoring in a cohort of 219 breast cancers. The mean, median and range of AR percent positivity by 
immunostaining are shown. (C) Left panel: an example of weak nuclear AR immunostaining in 
approximately 20% of the tumor cells. Right panel: an example of breast cancer with uniform nuclear AR 
immunoreactivity of moderate intensity in virtually 100% of tumor cells. Arrows denote examples of AR 
positive tumor cells. (D) Kaplan-Meier analysis showing that high AR (>78% nuclear positivity) was 
significantly associated with increased OS (log rank statistic=12.60, P <0.0001). (E) Kaplan-Meier analysis 
showing that breast tumors with high AR that were ERα positive (AR>78% ERα+) are associated with a 
significantly increased overall patient survival (log rank statistic=32.34, P <0.0001) when compared to the 
remaining tumor groups (AR<78% ERα+; AR>78% ERα- and AR<78% ERα-). (F) Cox regression analysis 
for OS comparing relative risk among AR and ERα sub-groups in (E); n=204. ERα+ denotes ERα >1% 
positive tumor nuclei; ERα- denotes ERα negative tumors. AR>78 denotes AR positivity greater than or 
equal to 78% and AR<78 refers to AR positivity less than 78%. HR, hazard ratio; CI, confidence interval. 
 
Figure 2. AR immunostaining and overall survival (OS) in the validation cohort. (A) Receiver 
operating characteristic (ROC) analysis in the validation cohort identified an area under the curve of 0.588 
(95% CI; 0.525-0.651, P=0.008). (B) Frequency distribution for AR was assessed by visual scoring in the 
validation cohort of 418 breast tumors. The mean, median and range of percent positivity by AR 
immunostaining are shown. (C) Left panel: an example of weak nuclear AR immunostaining in 
approximately 20% of tumor cells. Right panel: an example of strong AR nuclear immunoreactivity in 
approximately 80% of tumor cells. Arrows denote examples of AR positive tumor cells. (D) Kaplan-Meier 
analysis showing that high AR was significantly associated with increased OS (log rank statistic=12.07, 
P=0.001). (E) Kaplan-Meier analysis showing that breast tumors with high AR (>78% nuclear positivity) 
that were ERα positive (AR>78% ERα+) are associated with significantly increased OS (log rank 
statistic=20.12, P<0.0001) when compared to the remaining tumor groups (AR<78% ERα+; AR>78% ERα- 
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and AR<78% ERα). (F) Cox regression analysis for OS, comparing relative risk among the AR and ERα 
sub-groups in (E); n=344. ERα+ denotes ERα >1% tumor nuclei; ERα– denotes ERα negative tumors. 
AR>78 denotes AR positivity greater than or equal to 78% and AR<78 refers to AR positivity less than 
78%. HR, hazard ratio; CI, confidence interval. 
 
Figure 3. AR:ERα ratio predicts overall survival (OS). Analysis of the AR:ERα ratio in the combined 
training and validation cohorts (n=552) with cases separated into tertiles; AR:ERα ratio approximating 1 
(i.e. 0.87-1.05), AR:ERα ratio >1.05, AR:ERα ratio <0.87. For the 120 patients with ERα negative tumors, 
patients were divided into groups according to whether the tumors were AR high (≥ 78% nuclear positivity) 
or not (< 78% AR nuclear positivity).  Upper panel: Kaplan-Meier analysis showing the association between 
the different subgroups and OS (log rank statistic=37.4, P<0.0001). Lower panel: Cox regression analysis 
showing the relative risk of death in the different subgroups relative those with an AR:ERα ratio 
approximating 1. HR, hazard ratio; CI, confidence interval. 
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